SWX:NOVNPharmaceuticals
Novartis Targets PI3Kα Breast Cancer Therapy To Deepen Oncology Pipeline
Novartis (SWX:NOVN) agreed to acquire a selective breast cancer therapy targeting PI3Kα mutations from Synnovation Therapeutics for up to US$3b.
The oral therapy is aimed at HR+/HER2- breast cancer with PI3Kα mutations, addressing a major unmet treatment need.
The deal is intended to strengthen Novartis's targeted oncology portfolio in a competitive cancer drug market.
For investors watching big pharma, this move puts a fresh spotlight on Novartis's focus on targeted cancer medicines...